Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE fail to recommend AstraZeneca's cancer drug Olaparib on cost effectiveness basis

pharmatimesNovember 12, 2018

Tag: AstraZeneca’s , NICE , Advanced ovarian cancer

PharmaSources Customer Service